April 16, 2008 - -DiaKine Therapeutics today announced that its developmental drug Lisofylline (LSF), significantly reduced indicators of inflammation in visceral fat tissue that are predictive of heart disease and diabetes risk, according to results of a pre-clinical study presented at the Arteriosclerosis, Thrombosis and Vascular Biology Annual Conference 2008. “This study using ‘Western’ type high-fat, diet fed obese mice, suggests that medications with the actions of LSF could reduce inflammation and insulin resistance associated with central obesity – therefore providing a novel opportunity to treat heart disease and prevent type 2 diabetes development... [PDF] DiaKine's Press Release -
